(Dextran) Q-Med launches a pharmaceutical in Sweden

Sharon Grant · #1 (**permalink**) 07-16-2006, 10:23 PM

UPPSALA, Sweden | Jul 13, 2006 | Q-Med hereby announces that a pharmaceutical, CosmoferÂ® (low molecular iron dextran), has now been approved for sales in Sweden. It is estimated that sales will start towards the end of the year.

Q-Med has an agreement with the Danish manufacturer Nebo/Pharmacosmos (Pharmacosmos A/S - Intravenous Iron Infusion & Iron Injection Pharmaceuticals) concerning sales rights for the preparation on the Swedish market.

Cosmofer is given through an infusion in a vein or as an injection in a muscle. What is unique for Cosmofer is that the patient's total need can be given in a single dose. The product is used for the treatment of serious iron deficiency where treatment with tablets is not tolerated or does not have sufficient effect. The need can be seen above all in people with kidney disease, in cancer patients, in cases of inflammatory intestinal disease, during pregnancy and in connection with surgical procedures when it is desirable to avoid blood transfusions.

Q-Med has previous experience of intravenous iron and had sales of a similar preparation up until 1999.

WHO estimates that approximately 3 billion people, more than 30% of the world's population, have anemia, above all due to iron deficiency. In Sweden there are 4 oral iron products, which together have sales of SEK 28.5 million. Only one intravenous product exists today, Venofer, with sales of SEK 26.6 million during 2005.

Queries should be addressed to:

Erika Kjellberg Eriksson, CFO
Tel: + 46 (0) 70-974 90 20

In the US, Q-Med ABÂ´s affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden, Tel: 018-474 90 00, Fax: 018-474 90 01
info@q-med.com, Q-Med, Org.nr. 556258-6882

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes	Rate This Thread
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode	Rate This Thread:

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
Bayer Launches Phase III Clinical Study of TrasylolÂ® in Elective Spinal Fusion Surger	Jan B. Wade	News and Hot Topics such as Hepatitis C, SARS and AIDS	0	12-08-2005 02:27 PM
Alliance Pharmaceutical Corp. and Beijing Double-Crane Pharmaceutical Co., Ltd. Annou	Nika	Press Releases	0	04-05-2005 09:23 PM
Iron Dextran	Editors	Glossary of Terms	0	11-29-2003 03:17 PM
Dextran	Editors	Glossary of Terms	0	11-29-2003 02:58 PM
Trasylol - Bayer Launches New Campaign to Lower Blood Transfusions	Jan B. Wade	Shop Talk	0	07-29-2003 01:13 PM

(Dextran) Q-Med launches a pharmaceutical in Sweden

Welcome to the latest in bloodless medicine and blood transfusion alternatives.

We are a community of medical professionals and members of the public who are responding to the worldwide concern about the efficacy, cost and availability of donor blood.

Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)